ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 914,65
0,00%
Dow Jones
38 225,66
0,85%
DAX
17 896,50
-0,14%
Brent Oil
83,755
0,15%
Bitcoin
59 556,21
0,74%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Lipella Pharmaceuticals Inc (LIPO)

  7. Lipella Pharmaceuticals Inc (LIPO) Actualités

LIPO Lipella Pharmaceuticals Inc

0,775
0,0479 (6,59%)
03 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Lipella Pharmaceuticals Inc LIPO NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,0479 6,59% 0,775 01:49:29
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,725 0,722 0,76 0,75 0,7271
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
17/4/202414:00GLOBELipella Pharmaceuticals Expands its Advisory Board to..
05/4/202414:00GLOBELipella Pharmaceuticals to Publish Abstract Detailing..
03/4/202414:00GLOBELipella Pharmaceuticals Announces FDA Type C Meeting for..
07/3/202421:23GLOBEPRISM MarketView Spotlights Lipella Pharmaceuticals as it..
06/3/202423:05EDGAR2Form SC 13D/A - General statement of acquisition of..
06/3/202423:03EDGAR2Form SC 13D/A - General statement of acquisition of..
05/3/202414:00GLOBELipella Pharmaceuticals Announces FDA Clearance of IND for..
27/2/202423:04EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
27/2/202422:51EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
20/2/202414:00GLOBELipella Pharmaceuticals to Present at PropThink Digital..
09/2/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
07/2/202423:29EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01/2/202422:09EDGAR2Form S-3 - Registration statement under Securities Act of..
25/1/202422:06EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
03/1/202422:59EDGAR2Form SC 13G - Statement of acquisition of beneficial..
20/12/202314:00GLOBELipella Pharmaceuticals Marks Successful First Year with..
28/11/202323:28EDGAR2Form 8-K - Current report
22/11/202322:05EDGAR2Form 8-K - Current report
14/11/202312:22EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/11/202312:14EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/11/202314:00PRNUSFDA Grants Orphan Designation for Lipella's LP-310 Drug..
09/11/202322:07EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
01/11/202321:06EDGAR2Form S-1 - General form for registration of securities under..
25/10/202322:05PRNUSLipella Pharmaceuticals Announces Closing of $2 Million..
24/10/202314:00PRNUSLipella Pharmaceuticals Announces $2 Million Private..
20/10/202314:00PRNUSLipella Pharmaceuticals Announces FDA Clearance of IND for..
10/10/202322:05EDGAR2Form DEF 14A - Other definitive proxy statements
21/9/202314:30PRNUSLipella Pharmaceuticals' Phase 2a Clinical Study Results..
11/9/202313:38EDGAR2Form 8-K - Current report
14/8/202322:16EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/8/202322:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202322:30EDGAR2Form 8-K - Current report
02/8/202322:05EDGAR2Form 8-K - Current report
15/5/202315:17PRNUSLipella Pharmaceuticals Reports First Quarter 2023 Financial..

Dernières Valeurs Consultées

NASDAQ
LIPO
Lipella Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés